Form D · Pharmaceuticals
Regulus Therapeutics Inc.
San Diego, CA · CIK 0001505512
Offering snapshot reported Dec 6, 2021 · SEC filing
- Reported sold
- $34.6M Offering amount: $34.6M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 30, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 6, 2021 | Initial | $34,624,999 | No comparison | 16 | SEC filing |
| Dec 17, 2020 | Initial | $19,383,037 | No comparison | 18 | SEC filing |
| May 14, 2019 | Initial | $16,736,889 | No comparison | 21 | SEC filing |
| Feb 6, 2014 | Initial | $9,999,992 | No comparison | 1 | SEC filing |
| Oct 23, 2012 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Oct 23, 2012 | Initial | $25,000,000 | No comparison | 1 | SEC filing |
| Nov 15, 2010 | Initial | $29,800,000 | No comparison | 2 | SEC filing |
| Nov 15, 2010 | Initial | $9,999,996 | No comparison | 1 | SEC filing |
| Nov 15, 2010 | Initial | $20,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.08M
- Finders' fees
- $0
- Form D file number
- 021-423683
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H. C. Wainwright & Co., LLC | 375 | |
| SVB Leerink LLC | 39011 |
Source: Form D, filed Dec 6, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Aker | Executive |
| David Baltimore | Director |
| Grantland Bryce | Executive |
| Cris Calsada | Executive |
| Bruce L.A. Carter | Director |
| Daniel R. Chevallard | Executive |
| Kathryn J. Collier | Director |
| Stanley Crooke | Director |
| Denis Drygin | Executive |
| Mark G. Foletta | Director |
| Neil Gibson | Executive |
| Barry E. Greene | Director |
| Joseph Hagan | Director, Executive |
| Alice S. Huang | Director |
| John Maraganore | Director |
| Garry Menzel | Executive |
| Jake R. Nunn | Director |
| Stelios Papadopoulos | Director |
| B. Lynne Parshall | Director |
| William H. Rastetter | Director |
| Hugh Rosen | Director |
| Simos Simeonidis | Director |
| Douglas E. Williams | Director |
| Pascale Witz | Director |
| Kleanthis Xanthopoulos | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4224 Campus Point Court Suite 210
San Diego, CA, 92121
San Diego, CA, 92121